As GLP-1 agonists such as Zepbound continue to be widely prescribed for type 2 diabetes and obesity, clinicians must remain vigilant for functional GI complications, particularly when patients present with unexplained symptoms. This evidence concerns the gene GLP1R and obesity disorder.